— Arrowhead Pharmaceuticals
Inc. (NASDAQ: ARWR) reported earnings
of 69 cents per share during fiscal year 2019, compared to a loss of 65 cents
per share a year ago.
— For
the full year, revenue rose to $168.7 million,
vs. $16.1 million last year.
— During Q4, the company started dosing patients in an adaptive design Phase 2/3 trial, called SEQUOIA, with the potential to serve as a pivotal registrational study of ARO-AAT.
— ARWR
shares have more-than-quadrupled since the beginning of this year.